QUIKFLO HEALTH INC.

MANAGEMENT'S DISCUSSION & ANALYSIS
FOR THE NINE MONTHS ENDED APRIL 30, 2017

This management's discussion and analysis ("**MD&A**") discusses the activities and financial position of QuikFlo Health Inc. (the "**Company**") for the nine month period ended April 30, 2017. The following information should be read in conjunction with the unaudited interim consolidated financial statements of the Company as at and the audited consolidated financial statements of the Company for the period ended July 31, 2016 and the related notes contained therein, which have been prepared in accordance with International Financial Reporting Standards ("IFRS").

Additional information can be accessed through the System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedar.com, and the Company's website at www.vipergoldltd.com.

All dollar amounts are expressed in Canadian currency unless otherwise stated.

Date of Report – May 30, 2017 and presents material information up to this date.

Forward-Looking Statements

This MD&A may contain forward-looking statements relating to future events. In some cases, forward-looking statements can be identified by words such as "anticipate", "continue", "estimate", "expect", "forecast", "may", "will", "project", "should", "believe", or similar expressions. These forward-looking statements by their nature involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements, including the "Risks and Uncertainties" discussed in this MD&A. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect.

Brief Description of Business

The Company is a Canadian-based company whose focus was until May 8, 2014, mineral exploration. QuikFlo is a medical software company developing innovative solutions for the analysis of medical images, the primary focus of which is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

The Company has announced its intention to diversify into the medical marijuana field with the acquisition of a medical marijuana company located in Las Vegas, Nevada.

On September 1, 2015, the Company entered into an agreement dated with the shareholders of QuikFlo Technologies Inc. ("QuikFlo"), a private Alberta company, pursuant to which Viper will acquire all of issued and outstanding QuikFlo shares in exchange for 30 million common shares of Viper ("Viper Shares") at a deemed price of $0.10 per Viper Share (the "Transaction").

QuikFlo’s sole asset is the exclusive worldwide rights to intellectual property (the "QuikFlo Diagnostic Tool") that is being developed into an automated diagnostic tool which interprets computerized tomography ("CT") scans of ischemic stroke patients and provides specific treatment options to attending physicians. The Quikflo Technologies Inc. acquisition closed on November 23, 2015.

Additional information and details on the QuikFlo transaction can be found on the Management Information Circular dated September 30, 2015 which is filed on SEDAR.

Nature of Operations

Viper Gold Ltd. was incorporated pursuant to the provisions of the Business Corporations Act (Alberta) on January 29, 2008. The Company’s executive office is located at 430 – 580 Hornby Street, Vancouver, British Columbia, Canada. Viper Gold Ltd. changed its name to QuikFlo Health Inc. on November 23, 2015.

Acquisition of QuikFlo Technologies Inc.

On November 23, 2015, QuikFlo Health acquired a 100% ownership in QuikFlo Technologies by issuing 30,000,000 common shares to the shareholders of QuikFlo Technologies. For accounting purposes, this acquisition is accounted for as a reverse takeover transaction and recapitalization as the acquisition resulted in the former shareholders of QuikFlo Technologies having control of the combined entity. This was accounted for as an acquisition of assets of QuikFlo Health and not a business combination. Accounting for the acquisition as a reverse takeover results in the following:

i. The consolidated financial statements of the combined entities are issued as the consolidated financial statements of the legal parent, QuikFlo Health, but are considered a continuation of the financial statements of the legal subsidiary, QuikFlo Technologies.
ii. Since QuikFlo Technologies is deemed to be the acquirer for accounting purposes, its assets and liabilities are included in the consolidated financial statements at their historical carrying values.
iii. The deficit of QuikFlo Health up to the date of acquisition was eliminated.
iv. The number of shares issued in the consolidated entity is that of QuikFlo Health up to the RTO date on November 23, 2015, plus all shares issued on and after the RTO date. The dollar amount of the issued share capital in the consolidated statement of financial position immediately prior to acquisition is the dollar value of QuikFlo Technologies’ issued capital up to the RTO date on November 23, 2015 plus the value of all shares issued by the Company on and after the RTO

date, including the value of shares issued to acquire QuikFlo Technologies.

v. Change of fiscal year end from December 31 to July 31 to coincide with the fiscal year end of QuikFlo Technologies.

The fair value of the consideration paid by QuikFlo Technologies for the acquisition of QuikFlo Health this based on the fair value of equity instruments in the combined entities allocated to the existing shareholders in QuikFlo Health. The consideration paid by QuikFlo Technologies consists of the fair value of QuikFlo Health's common shares, share purchase options and share purchase warrants outstanding immediately before the date of the reverse takeover acquisition. The identifiable assets acquired and liabilities of QuikFlo Health assumed by QuikFlo Technologies are measured at their fair values at the acquisition date. Excess of the aggregate of the consideration transferred by QuikFlo Technologies over the fair value of the identifiable net assets acquired and liabilities of QuikFlo Health assumed by QuikFlo Technologies is attributable to the cost of obtaining a listing status. This amount is expensed as it does not meet the criteria for recognition as an asset.

The following are the fair values of QuikFlo Health's assets acquired and liabilities assumed by QuikFlo Technologies on November 23, 2015 and consideration paid by QuikFlo Technologies:

Net assets acquired:	$
Cash and cash equivalents	475,307
Prepaid expenses	34,301
Accounts payable and accrued liabilities	(252,091)
Total net assets acquired	257,517
Consideration paid:	
Fair value of QuikFlo Health's existing common shares deemed issued by QuikFlo Technologies (Note 6)	1,715,400
Fair value of QuikFlo Health's existing post consolidation share purchase warrants deemed granted by QuikFlo Technologies (Note 6)	515,200
Total consideration paid	2,230,600
Listing expense	1,973,083

INTANGIBLE ASSETS

*On July 27, 2015, the C*ompany acquired all of the rights, title and interest in and to the intellectual property rights and technology rights ("IP Rights") related to an automated imaging tool for quick and appropriate triage of stroke patients by way of an intellectual property assignment agreement. The intellectual property rights comprise a worldwide, perpetual right, title and interest in the invention and any improvements that may be afforded protection under laws of a given jurisdiction through the application and granting of a patent, trademark, copyright or other similar forms of intellectual property protection. The intellectual property rights include a United States provisional patent application that was filed on December 1, 2014. QuikFlo filed a regular utility patent application by December 1, 2015 to claim priority to and the benefit of the provisional patent filing date. If the full patent is granted in the United

States, the technology detailed in the patent will be protected for a period of 20 years. The technology rights comprise the right, title and interest in any technical information, know-how, processes, procedures, compositions, devices, methods, formulae, protocols, techniques, software, designs, drawings or data created. In consideration for the IP Rights, the Company issued 600 common shares to the inventors of the IP Rights with an estimated grant date fair value of $625 per common share based on the value of common shares issued for cash around the same date, for total consideration of $375,000. Additionally, the Company signed an Assignment Agreement with UTI Limited Partnership for the IP Rights. Pursuant to this agreement, the Company shall pay the following i) a running royalty of 1% of net sales; ii) royalty conversion at the time of a liquidation event or an Initial Public Offering ("IPO") equal to 1% of the aggregate consideration for a liquidation event or a valuation for an IPO; and iii) change of control fee equal to 2% of either the aggregate consideration for a liquidation event or a valuation for an IPO.

On February 12, 2016, the Company has reached agreement to enter into a worldwide non-exclusive license agreement with the University of Western Ontario (“Western”) to use certain CT perfusion intellectual property that has been developed by Dr. Ting Lee, the Company’s former Chief Technology Officer. This technology was assigned to Western by Dr. Lee, who is a professor at Western, in accordance with that university’s policies. This same technology has been an integral part of General Electric’s CT scanner programs for several years. In consideration for the license agreement, the Company issued 100,000 common shares to Western with a grant date fair value of $0.14 per common share, for total consideration of $14,000. Pursuant to this agreement, the Company shall pay the following i) a running royalty of 0.5% of net sales; ii) change of control fee equal to 0.5% of the aggregate consideration for a liquidation event.

PROPOSED MEDICAL MARIJUANA ACQUISITION

The Company recently entered into a letter of intent to acquire two US marijuana companies in Las Vegas, Nevada. The acquisitions include a 12,000 sq. ft. licensed medical marijuana cultivation/production facility and packaging center with over $1 million in medicinal sales in its first year of operation. The second acquisition is of a start-up company that develops and markets hemp based and CBD infused products for sales nationwide.

QuikFlo will acquire a non-arms’ length private company which has arms’ length agreements dated January 25, 2017 in place to acquire 91% of both the medical marijuana production facility company and the related infused product company. QuikFlo is currently undertaking a non-brokered private placement of up to $7,500,000, of which $6.1 million has been closed to date. Arms’ length finder’s fees are payable in the amount of 3 million shares. The Company is offering units at a price of $0.075 per unit, with each unit consisting of one common share and one half of a share purchase warrant entitling the holder to purchase one additional common share for $0.15 for a period of 2 years from closing. The warrants contain a forced conversion provision that if the shares of the Company trade at $0.25 or more for a period of 10 trading days, the Company has the option to accelerate the expiry date to no less than 30 days from a press release advising of the same. The Company will pay qualified finders a commission of 8% in cash and finder's warrants.

The Company anticipates paying approximately US $3.7 million and issuing approximately 60 million shares in respect to this transaction, in addition to the private placement shares. This transaction is subject to all conditions customary in acquisitions of this kind, including due diligence and regulatory approval from county and state health authorities. Although not a certainty, the Company anticipates closing this transaction in June, 2017.

Issued common shares

	Number of Shares	Amount $
Balance at July 31, 2015	601	372,555
Common shares issued for cash	400	250,000
Reverse takeover transaction (RTO) (Note 4)	(1,001)	-
RTO acquisition of QuikFlo Technologies (Note 4)	30,000,000	-
QuikFlo Health shares on RTO (Note 4)	8,577,200	1,715,400
Common shares issued for warrant exercise	700,000	144,300
Common shares issued for license acquisition (Note 5)	100,000	14,000
Balance at July 31, 2016	39,377,200	2,496,255
Common shares issued for cash	73,485,699	25,500
Common share issued costs	-	(305,174)
Balance at April 30, 2017	112,862,899	7,697,626

Prior to the reverse takeover, QuikFlo Technologies issued 400 common shares, to officers and directors of the Company, for total proceeds of $250,000.

During the year, the Company issued 700,000 common shares for warrants exercised for total proceeds of $35,000 (residual recorded in share based payments reserve).

The Company issued to Western 100,000 common shares for the license acquisition (Note 5).

During the nine month period ended April 30, 2017, the Company issued 318,750 units at $0.08 per unit for gross proceeds of $25,500. Each unit is made up of one common share and one common share purchase warrant, whereby each warrant is exercisable for one common share at a price of $0.20 per share for 18 months and the Company issued 73,166,949 units at $0.075 per unit for gross proceeds of $5,487,521. Each unit is made up of one common share and one common share purchase warrant, whereby each warrant is exercisable for one common share at a price of $0.15 per share for 24 months.

During the nine month period ended January 31, 2017, 3,475,000 stock options were forfeited, 3,400,000 of which were forfeited by directors and officers.

For the nine months ended April 30, 2017, the Company incurred a net loss of $721,597 or $0.01 per share. (2016 - $1,778,336 or $0.07 per share). For the three months ended April 30, 2017, the Company incurred a net loss of $545,987, or $0.01 per share (2016 - $230,757 or $0.01 per share).

The overall lower the management and consulting expenditures incurred in the nine months period ended April 30, 2017 is due to costs incurred towards investigating and reviewing various potential business opportunities, some of which are no longer under consideration, and less specifically costs incurred in the QuikFlo transaction.

Liquidity and Capital Resources

As at April 30, 2017, the Company had a working capital of $3,613,975 (April 30, 2016 – working capital deficiency $482,301). The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at April 30, 2017, the Company did have sufficient cash to settle current liabilities.

At April 30, 2017 the Company had a cash balance of $2,662,554, and at April 30, 2016 the Company had a cash balance of $17,412.

During the nine months ended April 30, 2017, the Company closed three non-brokered private placements of 73,485,699 units of the Company ("Units") at a price of $0.08 and $0.075 per Unit for aggregate gross proceeds of $5,506,546.

Selected Quarterly Financial Information

A summary of selected financial information for the periods indicated follows:

Net Revenue and Net Income (Loss) for the last six (6) quarters

	2017 Apr. 30	**2017 Jan. 31**	**2016 Oct. 31**	**2016 Jul. 30**	**2016 Apr. 30**	**2016 Jan. 31**
Revenue (net of royalties)						
Net Income/(Loss)	(545,987)	(239,089)	(113,290)	(2,721,208)	(230,757)	(722,815)
Basic/Diluted Income/(Loss) Per Share	(0.01)	(0.01)	(0.00)	(0.07)	(0.01)	(0.02)
Number of weighted Average shares Outstanding	49,296,093	39,695,950	39,695,950	39,377,200	39,231,644	30,602,000

No dividends have been declared or paid by the Company in any of the periods presented above. The Company does not anticipate declaring or paying any dividends on its Common Shares in the foreseeable future.

Commitments and Contingencies

The Company entered into a lease for office space for 12 months from February 1, 2017 to January 31, 2018. The Company has a rental commitment of $13,139 at January 31, 2018 (2017- $nil).

The Company entered into a consulting agreement, with a senior engineer, for 3.5 years from December 15, 2015 to January 1, 2019. The Company has a commitment of $199,056 at January 31, 2017 (2016 - $294,060).

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Compensation of Key Management and Related Party Transactions

The remuneration of directors and members of key management personnel during the six month period ended April 30, 2017 and 2016 were as follows:

	2017	**2016**
Compensation	373,867	849,308
Stock based compensation	(182,925)	288,768
Total	190,942	1,138,077

During the nine month period ended April 30, 2017, the Company incurred legal fees and share issue costs in the amount of $80,034 (2015 – $382,424 and $28,523) from a law firm of which a director of the Company is a partner. As at April 30, 2017, the Company owed the law firm $467,931 (2016 – $263,136). These amounts are unsecured, non-interest bearing with no fixed terms of repayment.

As at April 30, 2017, the Company owed directors and officers $10,000 (2016 - $18,000). These amounts are included in accounts payable and accrued liabilities on the statement of financial position and are unsecured, non-interest bearing with no fixed terms of repayment.

As at April 30, 2017, the Company had a loan from a director of the Company for $106,000 (2016 - $nil). This loan is unsecured, non-interest bearing with no fixed terms of repayment.

Outstanding Share Data

Details about the Company's capitalization as at April 30, 2017 are as follows:

Common shares issued and outstanding	112,862,899
Potential issuance of common shares – warrants	77,417,222
Stock options issued to directors, employees, officers and consultants	1,100,000

CAPITAL RISK MANAGEMENT

The Company defines capital as Shareholders' Equity which at April 30, 2017 was $4,002,975 (2016 - $(82,301). The Company manages its capital structure and makes adjustments to it, in order to have the funds available to support its exploration, development and operations activities.

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern in order to pursue the development of its intellectual property and maximize shareholder returns. The Company satisfies its capital requirements through careful management of its cash resources and by utilizing bank indebtedness or equity issues, as necessary, based on the prevalent economic conditions of both the industry and the capital markets and the underlying risk characteristics of the related assets. As at April 30, 2017, the Company had no bank debt (2016 - $nil).

Management reviews its capital management approach on an ongoing basis. There were no changes in the Company's approach to capital management during the nine months ended April 30, 2017 and for the year ended July 31, 2016. The Company is not subject to externally imposed capital requirement.

	As at April 30, 2017		As at April 30, 2016	
	Carrying Amount	**Fair Value**	**Carrying Amount**	**Fair Value**
Cash and short term investments	$ 4,460,353	4,460,353	$ 17,412	$ 17,412
Sales tax receivable and prepaid	137,929	137,929	27,950	27,950
Accounts payable and accrued liabilities	984,307	984,307	527,663	527,663

Financial instruments and risk management

Set out below is a comparison, by category, of the carrying amounts and fair values of all of the Company financial instruments that are carried in the financial statements and how the fair value of financial instruments is measured.

Fair values

Fair value represents the price at which a financial instrument could be exchanged in an orderly market, in an arm's length transaction between knowledgeable and willing parties who are under no compulsion to act. The Company classifies the fair value of the financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instrument.

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in the active market for identical assets or liabilities. The Company has no level 1 financial instruments.
- Level 2 fair value measurements are those derived from inputs other than quoted prices that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (derived from prices). Cash equivalents are classified as level 2 financial instruments; and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs). The Company has no level 3 financial instruments.

The carrying value of cash equivalents and accounts payable and accrued liabilities reflected in the statements of financial position approximate fair value because of the limited term of these instruments.

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk and market risk (currency fluctuations, interest rates and commodity prices. The Company's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Company's financial performance.

Credit Risk

Credit risk is the risk of loss associated with a counter party's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash and cash equivalents. Cash and cash equivalents are composed of financial instruments issued by large Canadian financial institutions with high investment grade ratings and are closely monitored by management. Management believes credit risk with respect to cash is minimal.

Market risk

Market risk is the risk that changes in foreign exchange rates, commodity prices, and interest rates will affect the Company's net earnings or the value of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable limits, while maximizing returns.

Foreign exchange risk

The Company does not currently hold significant balances in foreign currencies to give rise to foreign exchange risk. As at April 30, 2017, the Company had cash balances of $412 (2016 - $Nil) in U.S. dollars. Sensitivity to a plus or minus 5% change in the foreign exchange rate would not have had a material effect to the net loss for year.

However, if and when the medical marijuana acquisition closes, this will change. Significantly more of the Company's expenses and revenues are expected to be incurred in U.S. Dollars. While the Company intends to implement prudent exchange rate risk mitigation steps, changes in foreign exchange rates between the Canadian and U.S. dollars may have a significant impact on the Company's financial performance in the future.

Commodity price risk

The Company has no significant exposure to fluctuations in commodity prices. Manufacturing of the Company's biomedical products require certain industrial commodities; however, the cost for such raw materials is not considered material to the overall performance of the Company.

Interest rate risk

The Company is not exposed to interest rate risk as it has no revolving loan facilities.

Outlook

The current priority for the Company is to close its planned medical marijuana acquisition. With this acquisition, management feels it will be acquiring a business in a growing sector with significant cash flow potential. The Company is currently awaiting regulatory and stock exchange approval, and are expecting to close in June, 2017. There is no certainty that this transaction will close.

The Company is also continuing to develop its software product, while looking for a development partner as that product gets closer to market.

The ability of the Company to realize its software development business plan is dependent upon the Company being able to commercialize a product for sale, to finance research, development and commercialization costs and compete in a competitive marketplace for diabetes monitoring products. Although the Company believes it will be successful, there is no guarantee the Company will produce a product that is marketable or obtains consumer acceptance.